Perfil ventilatório e capacidade funcional de pacientes com mucopolissacaridoses
DOI:
https://doi.org/10.33233/fb.v18i1.757Abstract
Objetivos: Caracterizar o perfil ventilatório e a capacidade funcional de pacientes com mucopolissacaridoses (MPS). Métodos: O perfil ventilatório caracterizou-se pela espirometria e pela forma da caixa torácica. A capacidade funcional foi obtida pela distância percorrida no teste de caminhada de seis minutos (DTC6M) e por questionários funcionais, Childhood Health Assessment Questionaire (CHAQ) e Health Assessment Questionaire (HAQ). Resultados: Dezenove pacientes com MPS, maioria do sexo masculino 16 (84,2%) e com mediana e intervalo interquartilíco (IIQ) de idade de 13,4 (6,3) anos. O MPS VI foi o mais frequente, 57,9%. Alteração na espirometria em 17/18 pacientes, com predomínio para o distúrbio ventilatório restritivo (DVR), 72,2%. Apresentaram alteração da caixa torácica 73,7%. Houve piora da capacidade vital forçada (CVF) (% previsto) com o aumento da idade para todos os tipos (r = -0,37) e, ao retirar da análise o tipo II, a correlação aumentou consideravelmente (r = -0,726). A DTC6M em mediana e IIQ foi de 349 (106,5) metros, com variação mediana percentual, 64,7%, da distância percorrida prevista obtida pela equação de referência para indivíduos saudáveis, 575,2 (128,5) metros. Nos questionários funcionais, 13/19 pacientes tiveram leve comprometimento da capacidade funcional. Conclusão: Houve alterações da função pulmonar na espirometria, da caixa torácica e comprometimento da capacidade funcional.
Palavras-chave: mucopolissacaridoses, espirometria, teste de esforço, atividades cotidianas.
References
Muhlebach MS, Wooten W, Muenzer J. Respiratory manifestations in mucopolysaccharidoses. Paediatr Respir Rev 2011;12(2):133-8.
Yeung AH, Cowan MJ, Horn B, Rosbe KW. Airway management in children with mucopolysaccharidoses. Arch Otolaryngol Head Neck Surg 2009;135(1):73-9.
Guarany NR. Avaliação do efeito da terapia de reposição enzimática na capacidade funcional de pacientes com mucopolissacaridose [dissertação]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2011. 120p.
Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 2005;69(5):589-95.
Dinwiddie R. The lung in multi-system disease. Paediatr Respir Rev 2000;1(1):58-63.
Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: Management and Treatment Guidelines. Pediatrics 2009;123(1):19-29.
Morales-Blanhir JE, Vidal P, Damián C, Romero R, Jesús M de, Castro G, et al. Six-minute walk test: a valuable tool for assessing pulmonary impairment. J Bras Pneumol 2011;37(1):110-7.
McDonald A, Steiner R, Kuehl K, Turbeville S. Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr Rehabil Med 2010;3(2):119-27.
Anon. I consenso brasileiro sobre espirometria. J Pneumol 1996;22(3):105-64.
Sociedade Brasileira de Pneumologia e Tisiologia. Jornal Brasileiro de Pneumologia 2002. 260 p.
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152(3):1107-36.
Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127(6):725-34.
Rodrigues JC, Cardieri JMA, Bussamra MHCF, Nakaie CMA, Almeida MB, Silva Filho LVF, et al. Provas de função pulmonar em crianças e adolescentes. J Pneumol 2002; 28(3):207-21.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166(1):111-7.
Priesnitz CV, Rodrigues GH, Stumpf CS, Viapiana G, Cabral CP, Stein RT, et al. Reference values for the 6-min walk test in healthy children aged 6-12 years. Pediatr Pulmonol 2009;44(12):1174-9.
Iwama AM, Andrade GN, Shima P, Tanni SE, Godoy I, Dourado VZ. The six-minute walk test and body weight-walk distance product in healthy Brazilian subjects. Braz J Med Biol Res 2009;42(11):1080-5.
Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin S-P, Parini R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab 2013;109(1):54-61.
Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30(1):167-78.
Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37(12):1761-9.
Vacha-Haase T. Statistical significance should not be considered one of life’s guarantees: effect sizes are needed. Educ Psychol Meas 2001;61(2):219-24.
Development Core Team. {R: A language and environment for statistical computing}. Vienna: R Foundation for Statistical Computing; 2009. 409 p.
Lin S-P, Shih S-C, Chuang C-K, Lee K-S, Chen M-R, Niu D-M, et al. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment. Pediatr Pulmonol 2014;49(3):277-84.
Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167(3):267-77.
Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009;123(1):229-40.
Glamuzina E, Fettes E, Bainbridge K, Crook V, Finnegan N, Abulhoul L et al. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J Inherit Metab Dis 2011;34(3):749-54.
Harmatz P, Yu Z-F, Giugliani R, Schwartz IVD, Guffon N, Teles EL et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 2010;33(1):51-60.
Costa-Motta FM, Acosta AX, Abé-Sandes K, Bender F, Schwartz IVD, Giugliani R, et al. Genetic studies in a cluster of mucopolysaccharidosis type VI patients in Northeast Brazil. Mol Genet Metab 2011;104(4):603-7.
Vieira T, Schwartz I, Muñoz V, Pinto L, Steiner C, Ribeiro M et al. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Am J Med Genet A 2008;146A(13):1741-7.
Mogayzel PJ, Marcus CL. Skeletal dysplasias and their effect on the respiratory system. Paediatr Respir Rev 2001;2(4):365-71.
Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med Off J Am Coll Med Genet 2006;8(8):465-73.
Lima MP. Curso Básico ReequilÃbrio Tóracoabdominal [Internet]. Florianópolis; 2013. [citado 2014 Dez 12]. DisponÃvel em: URL: www.rtaonline.com.br
Wooten WI, Muenzer J, Vaughn BV, Muhlebach MS. Relationship of sleep to pulmonary function in mucopolysaccharidosis II. J Pediatr 2013;162(6):1210-5.
Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MCS, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005;115(6):e681-9.
Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004;144(5):581-8.
Raluy-Callado M, Chen W-H, Whiteman DA, Fang J, Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J Rare Dis 2013;8(1):101.
Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis 2014;9:32.
Published
Issue
Section
License
Authors are authorized for non-exclusive distribution of the version of the work published in this journal (eg, publishing in an institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
